TGFB1 and colorectal carcinoma: In CRC, CYP19A1 abnormalized vascular, inhibited CD8+ T cell function, and reduced the efficacy of anti-PD-1 therapy by upregulating immune suppressors (PD-L1, IL-6, and TGF-β).